DK3390448T3 - Intravesikal terapi af blærekræft - Google Patents

Intravesikal terapi af blærekræft Download PDF

Info

Publication number
DK3390448T3
DK3390448T3 DK16819062.7T DK16819062T DK3390448T3 DK 3390448 T3 DK3390448 T3 DK 3390448T3 DK 16819062 T DK16819062 T DK 16819062T DK 3390448 T3 DK3390448 T3 DK 3390448T3
Authority
DK
Denmark
Prior art keywords
bladder cancer
intravesical therapy
intravesical
therapy
bladder
Prior art date
Application number
DK16819062.7T
Other languages
Danish (da)
English (en)
Inventor
Kjetil Hestdal
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Application granted granted Critical
Publication of DK3390448T3 publication Critical patent/DK3390448T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK16819062.7T 2015-12-17 2016-12-19 Intravesikal terapi af blærekræft DK3390448T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522311.8A GB201522311D0 (en) 2015-12-17 2015-12-17 Use
PCT/EP2016/081798 WO2017103280A1 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer

Publications (1)

Publication Number Publication Date
DK3390448T3 true DK3390448T3 (da) 2024-07-22

Family

ID=55311161

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16819062.7T DK3390448T3 (da) 2015-12-17 2016-12-19 Intravesikal terapi af blærekræft

Country Status (12)

Country Link
US (2) US20180371101A1 (enExample)
EP (1) EP3390448B1 (enExample)
JP (1) JP2018538308A (enExample)
KR (1) KR102878726B1 (enExample)
CN (1) CN108699147B (enExample)
AU (1) AU2016372570B2 (enExample)
DK (1) DK3390448T3 (enExample)
ES (1) ES2981986T3 (enExample)
FI (1) FI3390448T3 (enExample)
GB (1) GB201522311D0 (enExample)
PL (1) PL3390448T3 (enExample)
WO (1) WO2017103280A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
MX2020005692A (es) * 2017-12-01 2020-09-25 Sbi Pharmaceuticals Co Ltd Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario.
EP4676462A1 (en) 2023-03-07 2026-01-14 Photocure ASA Therapy for bladder cancer
WO2026052815A1 (en) 2024-09-05 2026-03-12 Photocure Asa Use of hal in a method for predicting bladder cancer immunotherapy response

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ303251A (en) 1995-03-10 2000-10-27 Photocure Asa Use of esters of 5-aminolevulinic acid as photosensitising agents in photochemotherapy
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
PL2342226T3 (pl) * 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2739358B1 (en) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
JP6312659B2 (ja) 2012-05-31 2018-04-18 ジェネンテック， インコーポレイテッド Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法
CN108135934B (zh) * 2015-10-19 2024-09-10 永恒生物科技股份有限公司 通过组合疗法治疗实体或淋巴肿瘤的方法
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use

Also Published As

Publication number Publication date
GB201522311D0 (en) 2016-02-03
US20180371101A1 (en) 2018-12-27
AU2016372570B2 (en) 2024-01-18
FI3390448T3 (fi) 2024-07-10
BR112018012116A2 (en) 2018-12-04
KR20180094988A (ko) 2018-08-24
AU2016372570A1 (en) 2018-07-12
EP3390448A1 (en) 2018-10-24
WO2017103280A9 (en) 2017-11-09
US11066478B2 (en) 2021-07-20
CN108699147B (zh) 2022-11-01
WO2017103280A1 (en) 2017-06-22
CA3008548A1 (en) 2017-06-22
ES2981986T3 (es) 2024-10-14
KR102878726B1 (ko) 2025-10-29
PL3390448T3 (pl) 2024-09-16
CN108699147A (zh) 2018-10-23
JP2018538308A (ja) 2018-12-27
EP3390448B1 (en) 2024-06-05
US20190241672A1 (en) 2019-08-08
RU2018124866A3 (enExample) 2020-02-26
RU2018124866A (ru) 2020-01-17

Similar Documents

Publication Publication Date Title
IL255261A0 (en) Methods for treating cancer
PL3283527T3 (pl) Leczenie skojarzone nowotworów
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
IL263802A (en) Cancer treatment combinations
DK3851537T5 (da) Behandling af hyperbilirubinæmi
HUE059694T2 (hu) Készítmény rák kezelésére
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
DK3262066T4 (da) Genterapi
IL258521B1 (en) Combination therapy for the treatment of cancer
PL3197456T3 (pl) Leczenie nowotworów
DK3622953T3 (da) Kombinationsbehandling af cancer
EP3413927A4 (en) CANCER THERAPY
LT3576740T (lt) Vėžio gydymas
DK3307267T3 (da) Behandling af multipel sklerose
PT3134119T (pt) Tratamento do cancro
DK3393478T3 (da) Kombinationsterapi
IL246558A0 (en) Novel methods for treating cancer
EP3362091A4 (en) COMBINATION THERAPY
DK3532076T3 (da) Immunterapeutiske behandlinger af tumorer
IL254825A0 (en) Methods of treatment with taselisib
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
PL3390448T3 (pl) Terapia dopęcherzowa raka pęcherza moczowego
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
LT3324951T (lt) Peritoninis terapinis skystis
DK3407909T5 (da) Cancerbehandling